Page 1313 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

4 References

syndrome: relation to presenting features and clinical out- United Kingdom Haemophilia Centre Doctors’ Organisation.
comes in a prospective cohort of 142 patients. Blood. July 1, Blood. March 1, 2007;109(5):1870-1877.
2003;102(1):60-68. 110. Knoebl P, Marco P, Baudo F, et al. Demographic and clinical
93. Jacob S, Dunn BL, Qureshi ZP, et al. Ticlopidine-, clopidogrel-, data in acquired hemophilia A: results from the European
and prasugrel-associated thrombotic thrombocytopenic pur- Acquired Haemophilia Registry (EACH2). J Thromb Haemost.
pura: a 20-year review from the Southern Network on Adverse April 2012;10(4):622-631.
Reactions (SONAR). Semin Thromb Hemost. November 111. Baudo F, Collins P, Huth-Kuhne A, et al. Management of
2012;38(8):845-853. bleeding in acquired hemophilia A: results from the European
94. Frank C, Werber D, Cramer JP, et al. Epidemic profile of Acquired Haemophilia (EACH2) Registry. Blood. July 5,
Shiga-toxin-producing Escherichia coli O104:H4 outbreak in 2012;120(1):39-46.
Germany. N Engl J Med. November 10, 2011;365(19):1771-1780. 112. Zanon E, Milan M, Brandolin B, et al. High dose of human
95. Coppo P, Adrie C, Azoulay E, et al. Infectious diseases as a plasma-derived FVIII-VWF as first-line therapy in patients
trigger in thrombotic microangiopathies in intensive care unit affected by acquired haemophilia A and concomitant car-
(ICU) patients? Intensive Care Med. April 2003;29(4):564-569. diovascular disease: four case reports and a literature review.
96. Garg AX, Suri RS, Barrowman N, et al. Long-term renal prog- Haemophilia. January 2013;19(1):e50-e53.
nosis of diarrhea-associated hemolytic uremic syndrome: a 113. Collins P, Baudo F, Knoebl P, et al. Immunosuppression for
systematic review, meta-analysis, and meta-regression. JAMA. acquired hemophilia A: results from the European Acquired
September 10, 2003;290(10):1360-1370. Haemophilia Registry (EACH2). Blood. July 5, 2012;
97. Legendre CM, Licht C, Muus P, et al. Terminal complement 120(1):47-55.
inhibitor eculizumab in atypical hemolytic-uremic syndrome. 114. Sadler JE, Budde U, Eikenboom JC, et al. Update on the patho-
N Engl J Med. June 6, 2013;368(23):2169-2181. physiology and classification of von Willebrand disease: a
98. Rock GA, Shumak KH, Buskard NA, et al. Comparison of report of the Subcommittee on von Willebrand Factor. J Thromb
plasma exchange with plasma infusion in the treatment of Haemost. October 2006;4(10):2103-2114.
thrombotic thrombocytopenic purpura. Canadian Apheresis 115. Franchini M. The use of desmopressin as a hemostatic agent: a
Study Group. N Engl J Med. August 8, 1991;325(6):393-397. concise review. Am J Hematol. August 2007;82(8):731-735.
99. Pene F, Vigneau C, Auburtin M, et al. Outcome of severe 116. Windyga J, von Depka-Prondzinski M; European Wilate Study
adult thrombotic microangiopathies in the intensive care unit. Group. Efficacy and safety of a new generation von Willebrand
Intensive Care Med. January 2005;31(1):71-78. factor/factor VIII concentrate (Wilate(R)) in the management
100. Coppo P, Bussel A, Charrier S, et al. High-dose plasma infu- of perioperative haemostasis in von Willebrand disease patients
sion versus plasma exchange as early treatment of throm- undergoing surgery. Thromb Haemost. June 2011;105(6):
botic thrombocytopenic purpura/hemolytic-uremic syndrome. 1072-1079.
Medicine. January 2003;82(1):27-38. 117. Mannucci PM, Kempton C, Millar C, et al. Pharmacokinetics
101. Scully M, McDonald V, Cavenagh J, et al. A phase 2 study of the and safety of a novel recombinant human von Willebrand factor
safety and efficacy of rituximab with plasma exchange in acute manufactured with a plasma-free method: a prospective clinical
acquired thrombotic thrombocytopenic purpura. Blood. August trial. Blood. August 1, 2013;122(5):648-657.
18, 2011;118(7):1746-1753. 118. Collins P, Budde U, Rand JH, Federici AB, Kessler CM.
102. Molino D, De Lucia D, Gaspare De Santo N. Coagulation disor- Epidemiology and general guidelines of the management
ders in uremia. Semin Nephrol. January 2006;26(1):46-51. of acquired haemophilia and von Willebrand syndrome.
103. Gawaz MP, Dobos G, Spath M, Schollmeyer P, Gurland HJ, Haemophilia. July 2008;14(suppl 3):49-55.
Mujais SK. Impaired function of platelet membrane glycopro- 119. Franchini M, Lippi G. Acquired von Willebrand syndrome: an
tein IIb-IIIa in end-stage renal disease. J Am Soc Nephrol. July update. Am J Hematol. May 2007;82(5):368-375.
1994;5(1):36-46. 120. Tiede A, Rand JH, Budde U, Ganser A, Federici AB. How I
104. Lindsay RM, Friesen M, Aronstam A, Andrus F, Clark WF, treat the acquired von Willebrand syndrome. Blood. June 23,
Linton AL. Improvement of platelet function by increased fre- 2011;117(25):6777-6785.
quency of hemodialysis. Clin Nephrol. August 1978;10(2):67-70. 121. Heilmann C, Geisen U, Beyersdorf F, et al. Acquired von
105. Mannucci PM, Remuzzi G, Pusineri F, et al. Deamino-8-D- Willebrand syndrome in patients with extracorporeal life sup-
arginine vasopressin shortens the bleeding time in uremia. port (ECLS). Intensive Care Med. January 2012;38(1):62-68.
N Engl J Med. January 6, 1983;308(1):8-12. 122. Velik-Salchner C, Eschertzhuber S, Streif W, Hangler H, Budde U,
106. Chakraverty R, Davidson S, Peggs K, Stross P, Garrard C, Fries D. Acquired von Willebrand syndrome in cardiac patients.
Littlewood TJ. The incidence and cause of coagulopathies in an J Cardiothorac Vasc Anesth. October 2008;22(5):719-724.
intensive care population. Br J Haematol. May 1996;93(2):460-463. 123. Natorska J, Bykowska K, Hlawaty M, Marek G, Sadowski J,
107. Levi M, Opal SM. Coagulation abnormalities in critically ill Undas A. Increased thrombin generation and platelet activa-
patients. Crit Care. 2006;10(4):222. tion are associated with deficiency in high molecular weight
108. Delgado J, Jimenez-Yuste V, Hernandez-Navarro F, Villar A. multimers of von Willebrand factor in patients with moderate-
Acquired haemophilia: review and meta-analysis focused to-severe aortic stenosis. Heart. December 2011;97(24):
on therapy and prognostic factors. Br J Haematol. April 2023-2028.
2003;121(1):21-35. 124. Vincentelli A, Susen S, Le Tourneau T, et al. Acquired von
109. Collins PW, Hirsch S, Baglin TP, et al. Acquired hemophilia A in Willebrand syndrome in aortic stenosis. N Engl J Med. July 24,
the United Kingdom: a 2-year national surveillance study by the 2003;349(4):343-349.

Section07-O-ref.indd 4 1/21/2015 11:26:48 AM